WO2013041655A1 - Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv - Google Patents
Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv Download PDFInfo
- Publication number
- WO2013041655A1 WO2013041655A1 PCT/EP2012/068593 EP2012068593W WO2013041655A1 WO 2013041655 A1 WO2013041655 A1 WO 2013041655A1 EP 2012068593 W EP2012068593 W EP 2012068593W WO 2013041655 A1 WO2013041655 A1 WO 2013041655A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- salt
- lactone
- water
- cinchonidine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 60
- 239000000543 intermediate Substances 0.000 title description 23
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 title description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title description 3
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical class C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 claims abstract description 53
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 150000002596 lactones Chemical class 0.000 claims abstract description 34
- 239000002253 acid Substances 0.000 claims abstract description 31
- 239000007864 aqueous solution Substances 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 239000000243 solution Substances 0.000 claims abstract description 20
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 19
- 239000003960 organic solvent Substances 0.000 claims abstract description 19
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 15
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 10
- 239000003112 inhibitor Substances 0.000 claims abstract description 7
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 68
- 238000006243 chemical reaction Methods 0.000 claims description 43
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 30
- -1 bicyclic lactone amide Chemical class 0.000 claims description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 26
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 21
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 238000006722 reduction reaction Methods 0.000 claims description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- QLSTWGZDXAHREY-UHFFFAOYSA-N n-methylhex-1-en-1-amine Chemical compound CCCCC=CNC QLSTWGZDXAHREY-UHFFFAOYSA-N 0.000 claims description 5
- 150000003918 triazines Chemical class 0.000 claims description 5
- FKSHZARYGBOZDO-UHFFFAOYSA-N 4,5-dichloro-6-methoxytriazine Chemical compound COC1=NN=NC(Cl)=C1Cl FKSHZARYGBOZDO-UHFFFAOYSA-N 0.000 claims description 4
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 claims description 3
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 claims description 3
- WMWOMMJQVXRFAP-UHFFFAOYSA-N 5-chloro-4,6-dimethoxytriazine Chemical compound COC1=NN=NC(OC)=C1Cl WMWOMMJQVXRFAP-UHFFFAOYSA-N 0.000 claims description 3
- 150000001261 hydroxy acids Chemical class 0.000 claims description 3
- 125000000686 lactone group Chemical group 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- KVJUPZXQTMRLQJ-UHFFFAOYSA-M 4-(3,5-dimethoxy-2h-triazin-4-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].CON1NN=CC(OC)=C1[N+]1(C)CCOCC1 KVJUPZXQTMRLQJ-UHFFFAOYSA-M 0.000 claims description 2
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 claims description 2
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- RJLBLEIPNSPREJ-UHFFFAOYSA-N 4-hydroxycyclopentane-1,2-dicarboxylic acid Chemical compound OC1CC(C(O)=O)C(C(O)=O)C1 RJLBLEIPNSPREJ-UHFFFAOYSA-N 0.000 abstract description 25
- 150000003839 salts Chemical class 0.000 abstract description 22
- 239000000203 mixture Substances 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 241000711549 Hepacivirus C Species 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 229930194542 Keto Natural products 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 125000000468 ketone group Chemical group 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 0 C*[C@](C[C@@](C1)O)[C@@]1C(OCc1ccccc1)=O Chemical compound C*[C@](C[C@@](C1)O)[C@@]1C(OCc1ccccc1)=O 0.000 description 3
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 3
- 229940011051 isopropyl acetate Drugs 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000005809 transesterification reaction Methods 0.000 description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- CJSMOECOKYPHSC-UHFFFAOYSA-N 4-oxocyclopentane-1,2-dicarboxylic acid Chemical compound OC(=O)C1CC(=O)CC1C(O)=O CJSMOECOKYPHSC-UHFFFAOYSA-N 0.000 description 2
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000007273 lactonization reaction Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 150000003147 proline derivatives Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- UOHLFORSZYRAEG-UHFFFAOYSA-N 1-methoxycarbonylcyclohex-2-ene-1-carboxylic acid Chemical compound COC(=O)C1(C(O)=O)CCCC=C1 UOHLFORSZYRAEG-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- KMPWYEUPVWOPIM-NAHPKXJFSA-N C=CC1C(CC2)CC([C@@H](c3ccnc4c3cccc4)O)N2C1 Chemical compound C=CC1C(CC2)CC([C@@H](c3ccnc4c3cccc4)O)N2C1 KMPWYEUPVWOPIM-NAHPKXJFSA-N 0.000 description 1
- WUZBOJXXYMKMMF-UHFFFAOYSA-N COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F Chemical compound COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F WUZBOJXXYMKMMF-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101800001020 Non-structural protein 4A Proteins 0.000 description 1
- RIILLRKNISZLAU-UHFFFAOYSA-N O=C(C(CC(C1)O2)C1C2=O)OCc1ccccc1 Chemical compound O=C(C(CC(C1)O2)C1C2=O)OCc1ccccc1 RIILLRKNISZLAU-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005865 alkene metathesis reaction Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- BYGAVIIEJSUUHA-UHFFFAOYSA-N cyclopentane-1,1-dicarboxamide Chemical compound NC(=O)C1(C(N)=O)CCCC1 BYGAVIIEJSUUHA-UHFFFAOYSA-N 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical class OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- UMLMPTNZLQAUIS-UHFFFAOYSA-N dimethyl 3-oxocyclopentane-1,1-dicarboxylate Chemical compound COC(=O)C1(C(=O)OC)CCC(=O)C1 UMLMPTNZLQAUIS-UHFFFAOYSA-N 0.000 description 1
- GMKJWKXCHOWVDN-UHFFFAOYSA-N dimethyl 4-oxocyclopentane-1,2-dicarboxylate Chemical compound COC(=O)C1CC(=O)CC1C(=O)OC GMKJWKXCHOWVDN-UHFFFAOYSA-N 0.000 description 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 1
- 229960004419 dimethyl fumarate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical compound C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XDYRBRLMIGIKQW-UHFFFAOYSA-N n-cyclopentylhydroxylamine Chemical compound ONC1CCCC1 XDYRBRLMIGIKQW-UHFFFAOYSA-N 0.000 description 1
- KKIMETYRXLWWSD-UHFFFAOYSA-N n-methylhex-5-en-1-amine Chemical compound CNCCCCC=C KKIMETYRXLWWSD-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- UGLYZKRVGNAOLZ-UHFFFAOYSA-N propan-2-yl 2-propan-2-yloxy-2h-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)C)C(OC(C)C)C=CC2=C1 UGLYZKRVGNAOLZ-UHFFFAOYSA-N 0.000 description 1
- 150000004322 quinolinols Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- MBDNRNMVTZADMQ-UHFFFAOYSA-N sulfolene Chemical compound O=S1(=O)CC=CC1 MBDNRNMVTZADMQ-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/16—Preparation of optical isomers
- C07C231/18—Preparation of optical isomers by stereospecific synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Definitions
- the present invention relates to synthesis procedures and synthesis intermediates of a macrocyclic protease inhibitor of the hepatitis C virus (HCV).
- HCV hepatitis C virus
- HCV Hepatitis C Virus
- liver transplantations hepatocellular carcinoma
- HCV NS3 serine protease and its associated cofactor, NS4A Replication of the genome of HCV is mediated by a number of enzymes, amongst which is HCV NS3 serine protease and its associated cofactor, NS4A.
- HCV NS3 serine protease and its associated cofactor, NS4A Various agents that inhibit this enzyme have been described.
- WO 05/073195 discloses linear and macrocyclic NS3 serine protease inhibitors with a central substituted proline moiety and WO 05/073216 with a central cyclopentane moiety. Amongst these, the macrocyclic derivatives are attractive by their pronounced activity against HCV and attractive pharmacokinetic profile.
- WO 2007/014926 describes macrocyclic cyclopentane and proline derivatives including the compound of formula I, with the structure represented hereafter.
- the compound of formula I is a very effective inhibitor of the HCV serine protease and is particularly attractive in terms of pharmacokinetics. Due to its favourable properties it has been selected as a potential candidate for development as an anti-HCV drug.
- the compound of formula I can be prepared starting from the bicyclic lactone carboxylic acid referred to as compound 39 in example 4, or in the general description of this reference as compound 17b, or as compound II in this description and claims.
- the carboxylic acid in bicyclic lactone carboxylic acid is coupled with N-methylhex-5-enylamine 38, followed by lactone opening to 4-hydroxy- cyclopentane derivative 4L
- the latter derivative 4J_ is then coupled with aminocyclo- propylcarboxylic ester to cyclopentane dicarboxylic acid diamide 43, which is coupled with quinoline 36 in an Mitsunobu ether- forming reaction, which involves an inversion at the hydro xy-bearing carbon.
- the resulting intermediate 44 is cyclized via a metathesis reaction to a macrocyclic derivative, in which the ester group is hydro lysed and coupled with cyclopropylsulfonylamide to yield the desired end product of formula I.
- R represents Ci_ 4 alkyl and in example 4, R is ethyl.
- the enantiomercally pure bicyclic lactone 39 was prepared starting from an enantiomer of 3,4-bis(methoxycarbonyl)cyclo-pentanone, referred to as (17a) in WO 2007/014926. The latter was prepared as described by Rosenquist et al. in Acta Chemica
- the trans (3R,4R)-3,4-bis(methoxycarbonyl) cyclopentanone diester (17a) was converted to the bicyclic lactone 17b (also referred to as compound II, see above), first by a keto to alcohol reduction, followed by hydrolysis of the esters, and lactone formation.
- the synthesis procedure for preparing I described in WO 2008/092955 starts from an intermediate D, wherein the ester function is hydrolysed, and coupled with cyclopropyl amino acid ester C.
- the resulting intermediate B is cyclized by an olefin metathesis reaction to the macrocyclic ester A, which is hydrolyzed and coupled with
- R is Ci_ 4 alkyl, in particular R is ethyl.
- R 1 is Ci_ 4 alkyl, in particular R 1 is methyl or ethyl.
- R 1 is in this scheme is as specified above and Bn represents benzyl.
- WO 2008/092955 furthermore describes procedures for preparing intermediate HJ_ starting from 4-oxo-l,2,-cyclopentanedicarboxylic acid O, by a keto to alcohol reduction, thus obtaining 4-hydroxy-l,2-cyclopentanedicarboxylic acid N, which in turn is cyclized to the bicyclic lactone M- Esterification of the carboxylic acid group in the latter yields the lactone benzyl ester L, wherein the lactone is opened by a transesterification reaction in the presence of a Ci_ 4 alkanol, thus yielding intermediate H, which is resolved in its enantiomers HJ_ and H2, as outlined in the following reaction scheme:
- a disadvantage of the above process is that it involves a resolution of the enantiomers of H by chiral column chromatography, a cumbersome procedure that is difficult to run at large scale production. Another disadvantage is that the resolution takes place at a later stage of the synthesis, whereby half of the building block H has to be discarded.
- Compound HJ_ is one of the two enantiomers obtained by separation from the racemic compound H.
- the other enantiomer is compound H2.
- the bicyclic lactone (17b) is an interesting building block in the synthesis of the compound of formula I. Finding a synthesis path to obtain this lactone in good yield and high enantiomeric purity is a desirable goal to achieve.
- the present invention provides such a process.
- WO 2010/072742 describes the use of the cinchonidine salt of the aforementioned bicyclic lactone as an intermediate in the preparation of intermediate (IX), and therefore also in the preparation of the HCV inhibitor (I).
- the cinchonidine salt (IV) is prepared via the resolution of a diastereoisomeric salt mixture (III) by selective crystallization.
- the salt (III) in turn is obtained by forming the cinchonidine salt of the racemic bicyclic lactone carboxylic acid (II), as outlined in the following reaction scheme:
- the invention in one aspect, provides a process for the preparation of a cinchonidine salt of formula (IV) comprising the steps of:
- steps (a), (b) and (c) are performed (not necessarily followed by steps (d) and (e)), although preferably all steps (a) to (e) are performed consecutively.
- steps (d) and (e) are performed, which are not necessarily preceded by all of steps (a), (b) and (c) (although they preferably are).
- the compounds employed in the processes described herein may be in the non-salt forms or they may be in the salt forms.
- the compound of formula (VI) may exist in a salt form when employed in the processes described herein, e.g. it may exist as a bis-salt, wherein the salt is for instance an inorganic metal e.g. Na or K (or the like) or the salt is an amine (e.g. an organic amine such as triethylamine or N-methylmorpholine, or the like).
- Examples of formula (VI) include the bis-potassium salt and the bis-triethylamine salt.
- the salt of formula (VI) is in an aqueous solution, there may be dis-association (to a certain degree).
- the compound of formula (VI) may be employed in the form of a salt (e.g. a bis-salt).
- Such a reaction may conveniently be preceded by a reaction that is performed in the presence of water, e.g. the reduction of racemic compound (V) to racemic compound (VI) (see step (a) described herein).
- step (a) may be performed in the presence of a base and hence the compound of formula (VI) may form a salt with the base employed (e.g. Na, K, triethylamine, N-methylmorpholine or diisopropylethylamine).
- the base employed e.g. Na, K, triethylamine, N-methylmorpholine or diisopropylethylamine.
- any association between (VI) and the counterion i.e. "salt"
- any salt of (VI) formed need not be isolated or purified in subsequent steps, given that the process described hereinbefore for preparing the lactone (II) is characterised in that it is performed in the presence of water.
- an organic solvent e.g. water-miscible organic solvent
- step (b) described hereinbefore i.e. in the step immediately preceding the lactone-forming step to produce (II).
- the lactone-forming step can be performed in water, especially since water is removed a by-product of the reaction and hence it is surprising that the reaction proceeds as described herein.
- water that is employed in reaction steps need not be removed for subsequent reaction steps (e.g. between the step (V) to (VI) and the step (VI) to (II), or, between the step (VI) to (II) and step (II) to (III) to (IV).
- a process for the preparation of a cinchonidine salt of formula (III) or (IV) comprises contacting cinchonidine with racemic lactone acid (II), characterised in that the reaction is performed in the presence of water.
- the reaction may also be performed in the presence of water mixed with an organic solvent, and hence this reaction may conveniently directly proceed the processes described herein for the preparation of the lactone acid (II).
- the invention provides a process for the preparation of an
- the invention provides a process for the preparation of compound (I) comprising preparing the cinchonidine salt as described above, followed by preparing compound IX as described above, and using compound (IX) as an intermediate in the synthesis of (I).
- the process of the invention starts with providing the 4-oxo-l,2-cyclopentane- dicarboxylic acid (V).
- the racemic 4-oxo-l,2-cyclopentanedicarboxylic acid V starting material can be prepared as described above in the Background of the Invention section.
- the keto acid (V) is subjected to reduction in an aqueous environment, thus providing an aqueous solution of racemic 4-hydroxy-l,2-cyclopentanedicarboxylic acid (VI).
- the keto to hydroxy reduction to convert V into VI can be done using a suitable reductant, in particular by hydrogen in the presence of a metal catalyst, e.g. rhodium on carbon or on alumina or Raney Ni, in a reaction- inert solvent, e.g. in an aqueous medium, such as water, in the presence of a base, e.g. NaOH, KOH, or an organic base such as triethylamine, N-methylmorpholine or Hunig's base (diisopropylethylamine).
- a suitable reductant in particular by hydrogen in the presence of a metal catalyst, e.g. rhodium on carbon or on alumina or Raney Ni
- a reaction- inert solvent e.g. in an aque
- an organic co-solvent e.g. a water-miscible organic co-solvent
- the organic co-solvent should be inert towards the reaction conducted, and should be (e.g. when it is a water-miscible organic co-solvent) sufficiently water-miscible so as to form a single phase solvent system.
- the solvent system need not necessarily be a single phase solvent system (e.g.
- Suitable water-miscible organic co-solvents include ketones, such as acetone or methylethylketone (MEK), ethers, such as tetrahydrofuran (THF) or 2-methyltetrahydrofuran (MeTHF), or acetonitrile.
- the preferred solvent in this step is acetone.
- Other solvents that may be mentioned are not necessarily water-miscible, for instance they may be non water-miscible or at least only moderately water-miscible, e.g. an aromatic solvent such as toluene or benzene.
- racemic hydroxyacid (VI) which is present in solution in the aqueous- organic solvent mixture, is subjected to cyclization, so as to obtain an aqueous-organic solvent solution of the corresponding racemic lactone acid (II).
- the cyclization can be conducted with known lactone- forming agents (or those mentioned herein, e.g.
- triazines such as a chloro formate, e.g. with ethyl or methyl chloro formate.
- a base can be added, e.g. a tertiary amine such as triethylamine or N-methylmorpholine (NMM).
- NMM N-methylmorpholine
- the lactone-forming agent is a triazine, more preferably 2,4,6-trichloro-l,3,5-triazine (TCT) or a derivative thereof.
- Triazine derivatives for this reaction comprise agents such as 2,4,6-trichloro- 1,3, 5 -triazine (TCT), chloro-dimethoxytriazine (CDMT), N-(3,5-dimethoxytriazinyl)- N-methylmorpholinium chloride (DMTMM) or dichloro-methoxytriazine (DCMT).
- TCT 2,4,6-trichloro- 1,3, 5 -triazine
- CDMT chloro-dimethoxytriazine
- DTMM N-(3,5-dimethoxytriazinyl)- N-methylmorpholinium chloride
- DCMT dichloro-methoxytriazine
- cinchonidine is added.
- this goes without the need to isolate the intermediate lactone acid (II).
- cinchonidine is added to the aqueous-organic solvent solution of the lactone acid (II), so as to obtain the cinchonidine salt (III) thereof.
- the enantiomerically pure cinchonidine salt (IV) can be isolated by crystallization, which provides an elegant way to resolve the stereochemistry of the bicyclic lactone acid (II), so as to obtain the desired lactone acid in high enantiomeric purity. Recrystallization or reslurrying allows further purification of this salt.
- the invention further provides a process for the preparation of an intermediate (IX) for the preparation of a HCV inhibitor compound of formula I.
- This process first comprises the steps of preparing an enantiomerically purified crystalline lactone acid cinchonidine salt (IV) as described above. Thereupon, the lactone acid cinchonidine salt (IV) is further reacted as described in WO 2010/072742. This preferably entails the reaction of the the lactone acid cinchonidine salt (IV) with N-methyl-hexenamine (NMHA) (VII) in an amide-forming reaction to yield the bicyclic lactone amide (VIII). Therein the lactone group is opened to yield the desired product (IX), as illustrated in the scheme below, wherein R 1 is Ci_ 4 alkyl, and preferably methyl:
- the reaction of the cinchonidine salt (IV) with NMHA (VII) is an amide forming reaction, which comprises reacting the starting materials with an amide-coupling reagent in a reaction- inert solvent, optionally in the presence of a base.
- Solvents that can be used comprise halogenated hydrocarbons such as dichloromethane (DCM) or chloroform, ethers such as tetrahydrofuran (THF) or 2-methyltetrahydrofuran
- MeTHF MeTHF
- alcohols such as methanol or ethanol
- hydrocarbon solvents such as toluene or xylene
- dipolar aprotic solvents such as DMF, DMA, acetonitrile, or mixtures thereof.
- dichloromethane MeTHF
- methanol ethanol
- ethanol toluene
- mixtures thereof Preferred are dichloromethane, MeTHF, methanol, ethanol, toluene, or mixtures thereof.
- Amide-coupling agents comprise agents such as N-ethoxycarbonyl- 2-ethoxy- 1 ,2-dihydroquinoline (EEDQ), N-isopropoxycarbonyl-2-isopropoxy- 1 ,2- dihydroquinoline, in particular its hydrochloride salt, (IIDQ), N ⁇ N ⁇ -tetramethyl- O-(7-azabenzotriazol-l-yl)uronium hexafluorophosphate (HATU), benzotriazol-l-yl- oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (commercially available as PyBOP ® ), ⁇ , ⁇ -Carbonyldiimidazole (CDI), l-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDI or EDCI) as well as its hydrochloride salt, dicyclohexyl- carbodiimide (DCC), or 1
- a catalyst may be added, for example 1-hydroxybenzotriazole (HOBt) or 4-dimethylaminopyridine (DMAP).
- HOBt 1-hydroxybenzotriazole
- DMAP 4-dimethylaminopyridine
- the reaction is usually conducted in the presence of a base, in particular an amine base such as a tertiary amine, e.g. triethylamine, N-methylmorpholine,
- ⁇ , ⁇ -diisopropylethylamine (the latter also being referred to as Hunig's base, DIPEA, or DIEA).
- Hunig's base DIPEA, or DIEA
- no base is used.
- the reaction is conducted in DCM or MeTHF with EEDQ, optionally with addition of methanol at the end of the reaction, at reflux temperature of the reaction mixture.
- the salt (IV) can be split into cinchonidine and the bicyclic lactone, and the latter can be reacted with NMHA in an amide forming reaction as described above.
- the lactone functionality in the resulting bicyclic lactone amide (VIII) is opened by a transesterification reaction with an alcohol, which may also serve as a solvent, in particular a Ci_ 4 alkanol such as methanol or ethanol, in the presence of an acid.
- Acids that can be used are strong organic acids such as sulfonic acids, in particular methanesulfonic acid.
- a solvent can be added such as an ether, in particular THF or MeTHF; or hydrocarbon solvents such as toluene or xylene.
- the transesterification reaction yields the ester of the alcohol that is used, e.g. when conducting the reaction in methanol, the methyl ester is formed.
- Ci_ 4 alkyl defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as for example methyl and ethyl; and also 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2 -methyl- 1 -propyl, 2-methyl-2- propyl.
- the generally accepted convention for representing stereochemical compounds, which is also adhered to herein is the following: - A compound represented without stereobonds, is racemic or the configuration of the stereogenic center(s) is not defined.
- a compound represented with stereobonds but without the descriptors "( ⁇ )", “rel”, or “rac” refers to a non-racemic compound (scalemic substance) i.e.enantio-enriched.
- enantiomeric purity is given as enantiomeric ratio (e.r.).
- e.r. value refers to the ratio of the two enantiomers of the acid in the mixture of diastereomeric salts.
- Example 1 to a suspension of 32.7 g (0.19 mol) of racemic 4-oxo- 1 ,2-cyclopentane- dicarboxylic acid (intermediate V) in 237.5 ml water under an atmosphere of nitrogen is added 1.0 ml (0.019 mol) 50% wt/wt aqueous NaOH. The mixture is warmed to 60°C and 2.5 g Rh/C (5%> wt/wt) are added. Then the reaction flask is purged with hydrogen and kept under an atmosphere of hydrogen while stirring until complete conversion is reached. The warm reaction mixture is filtered over Celite and the filter cake washed twice with 10 ml water.
- Triethylamine (55.61 ml, 0.40 mol) is added and 80%) of the solvent volume is distilled off under a pressure of 30 mbar.
- the reaction flask was fitted with a Dean-Stark trap filled with 2-methyltetrahydrofuran.
- an aqueous solution of VI (optionally in the form of a salt) is collected (after reduction of intermediate V) before removal of the water (via a
- NMM N-methylmorpholine
- the crude wet product (33.6 g) was loaded into a reactor, 140.2 mL of ethanol and 5.5 mL of water were added, and the mixture was heated and stirred at 77°C for 3 hours. The mixture was allowed to cool with stirring to 23°C over 2 hours, then stirred 12.5 hours at 22°C. The solids were filtered and washed with 11.4 mL of ethanol, and dried under vacuum at 50°C for 4 hours to give 26.2 g of (IV) with the following analytical characteristics: chemical purity - acid titration 99.4 w/w % and base titration 100 w/w %; chiral purity - e.r. 96.5/3.5
- Example 2 735 mg of 23.7 w/w% aqueous solution of VI, bis-potassium salt (1 mmol) was diluted in 4 ml water and mixed with 728 of NMM (6.6 mmol). 406 mg (2.2 mmol) TCT was added and the reaction mixture was stirred overnight at room temperature before dilution to a final volume of 10 ml to give a 78 mM aqueous solution of II ( yield: 78%).
- Example 3 728 of NMM (6.6 mmol) was mixed with 4 ml water and 406 mg (2.2 mmol) TCT was added. The mixture was stirred a few minutes before adding 735 mg of 23.7 w/w% aqueous solution of VI, bis-potassium salt (1 mmol). The resulting reaction mixture was further stirred overnight at room temperature before dilution to a final volume of 10 ml to give a 57 mM aqueous solution of II ( yield: 57%).
- Example 4 735 mg of 23.7 w/w% aqueous solution of VI, bis-potassium salt (1 mmol) was diluted in 4 ml water and mixed with 221 NMM (2 mmol). 648 mg (2.2 mmol) DMTMM.H 2 0 was added and the reaction mixture was stirred overnight at room temperature before dilution to a final volume of 10 ml to give a 54 mM aqueous solution of II ( yield: 54%).
- Example 5 386 mg (2.2 mmol) CDMT was dissolved in 4 ml acetone and 463 ⁇ (4.2 mmol) NMM was added.
- Example 6 386 mg (2.2 mmol) CDMT was dissolved in 4 ml MeTHF and 463 ⁇ (4.2 mmol) NMM was added. The mixture was stirred a few minutes then 735 mg of 23.7 w/w% aqueous solution of VI, bis-potassium salt was added. The resulting mixture was further stirred overnight at room temperature before dilution to a final volume of 10 ml to give a 54 mM solution of II (yield: 54%).
- Example 7 5.66 g (32.2 mmol) CDMT was dissolved in 59 ml MeTHF. 3.7 ml (33.7 mmol) NMM was added and the mixture was stirred lh at 25°C. 10.0 g of
- Example 8 5.66 g (32.2 mmol) CDMT was dissolved in 59 ml isopropyl acetate.
- Example 9 5.66 g (32.2 mmol) CDMT was dissolved in 59 ml acetone. 3.7 ml (33.7 mmol) NMM was added and the mixture was stirred lh at 25°C. 10.0 g of
- Example 10 19.80 g (113 mmol) CDMT was dissolved in 205 ml MeTHF. 13 ml (118 mmol) NMM was added and the mixture was stirred at 25°C for 2h. 35 g of 25.5 w/w% aqueous solution of bis N-methylmorpholine salt of VI (51.3 mmol) was added and the reaction mixture was stirred overnight at 25°C. 51 ml water and 10.6 ml concentrated HC1 were added and the mixture was stirred a few minutes at 25°C. The resulting solid was filtered off and the filtrate was decanted. The organic layer was washed with 51 ml water and 26 ml brine to give 181.7 g of 2.13 w/w % II solution in MeTHF (yield: 48 %).
- Example 11 19.80 g (113 mmol) CDMT was dissolved in 205 ml MeTHF. 13 ml (118 mmol) NMM was added and the mixture was stirred at 25°C for 2h. 35 g of 25.5 w/w% aqueous solution of bis N-methylmorpholine salt of VI (51.3 mmol) was mixed with 14.3 ml (102.5 mmol) triethylamine then added to the mixture of CDMT and bis N-methylmorpholine salt of VI (NMM) and the reaction mixture was stirred overnight at 25°C. 51 ml water and 19.9 ml concentrated HC1 were added and the mixture was stirred a few minutes at 25°C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112014006984A BR112014006984A2 (en) | 2011-09-22 | 2012-09-21 | processes and intermediates for the preparation of a macrocyclic hcv protease inhibitor |
CN201280046217.5A CN103906739B (en) | 2011-09-22 | 2012-09-21 | For preparation method and the intermediate of the macrocyclic protease inhibitor of HCV |
JP2014531241A JP6235473B2 (en) | 2011-09-22 | 2012-09-21 | Methods and intermediates for producing macrocyclic HCV protease inhibitors |
CA 2845720 CA2845720A1 (en) | 2011-09-22 | 2012-09-21 | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
EP12762583.8A EP2758386A1 (en) | 2011-09-22 | 2012-09-21 | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
KR20147007588A KR20140063726A (en) | 2011-09-22 | 2012-09-21 | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
AU2012311461A AU2012311461B2 (en) | 2011-09-22 | 2012-09-21 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV |
EA201490675A EA201490675A1 (en) | 2011-09-22 | 2012-09-21 | METHODS AND INTERMEDIATE COMPOUNDS FOR OBTAINING A MACROCYCLIC INHIBITOR OF HCV PROTEASE |
MX2014003509A MX356686B (en) | 2011-09-22 | 2012-09-21 | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv. |
US14/345,980 US9227965B2 (en) | 2011-09-22 | 2012-09-21 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV |
IL231024A IL231024A (en) | 2011-09-22 | 2014-02-18 | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
HK14113084.4A HK1199449A1 (en) | 2011-09-22 | 2014-12-31 | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv hcv |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11182375.3 | 2011-09-22 | ||
EP11182375 | 2011-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013041655A1 true WO2013041655A1 (en) | 2013-03-28 |
Family
ID=46924427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/068593 WO2013041655A1 (en) | 2011-09-22 | 2012-09-21 | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
Country Status (16)
Country | Link |
---|---|
US (1) | US9227965B2 (en) |
EP (1) | EP2758386A1 (en) |
JP (1) | JP6235473B2 (en) |
KR (1) | KR20140063726A (en) |
CN (2) | CN103906739B (en) |
AR (1) | AR087993A1 (en) |
AU (1) | AU2012311461B2 (en) |
BR (1) | BR112014006984A2 (en) |
CA (1) | CA2845720A1 (en) |
CL (1) | CL2014000687A1 (en) |
EA (1) | EA201490675A1 (en) |
HK (1) | HK1199449A1 (en) |
IL (1) | IL231024A (en) |
MX (1) | MX356686B (en) |
TW (1) | TWI565704B (en) |
WO (1) | WO2013041655A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016157058A1 (en) | 2015-03-27 | 2016-10-06 | Janssen Pharmaceuticals, Inc. | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005073195A2 (en) | 2004-01-30 | 2005-08-11 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
WO2007014926A1 (en) | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
WO2008092955A1 (en) | 2007-02-01 | 2008-08-07 | Tibotec Pharmaceuticals Ltd. | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
WO2010072742A1 (en) | 2008-12-23 | 2010-07-01 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
WO2011113859A1 (en) * | 2010-03-16 | 2011-09-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8426360B2 (en) * | 2007-11-13 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Carbocyclic oxime hepatitis C virus serine protease inhibitors |
MX2012003500A (en) * | 2009-09-28 | 2012-08-01 | Intermune Inc | Cyclic peptide inhibitors of hepatitis c virus replication. |
-
2012
- 2012-09-21 AR ARP120103498 patent/AR087993A1/en unknown
- 2012-09-21 KR KR20147007588A patent/KR20140063726A/en not_active Application Discontinuation
- 2012-09-21 EA EA201490675A patent/EA201490675A1/en unknown
- 2012-09-21 EP EP12762583.8A patent/EP2758386A1/en not_active Withdrawn
- 2012-09-21 US US14/345,980 patent/US9227965B2/en not_active Expired - Fee Related
- 2012-09-21 MX MX2014003509A patent/MX356686B/en active IP Right Grant
- 2012-09-21 CN CN201280046217.5A patent/CN103906739B/en not_active Expired - Fee Related
- 2012-09-21 AU AU2012311461A patent/AU2012311461B2/en not_active Ceased
- 2012-09-21 BR BR112014006984A patent/BR112014006984A2/en not_active IP Right Cessation
- 2012-09-21 CA CA 2845720 patent/CA2845720A1/en active Pending
- 2012-09-21 JP JP2014531241A patent/JP6235473B2/en not_active Expired - Fee Related
- 2012-09-21 CN CN201610933386.0A patent/CN107011339A/en active Pending
- 2012-09-21 WO PCT/EP2012/068593 patent/WO2013041655A1/en active Application Filing
- 2012-09-21 TW TW101134606A patent/TWI565704B/en not_active IP Right Cessation
-
2014
- 2014-02-18 IL IL231024A patent/IL231024A/en active IP Right Grant
- 2014-03-20 CL CL2014000687A patent/CL2014000687A1/en unknown
- 2014-12-31 HK HK14113084.4A patent/HK1199449A1/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005073195A2 (en) | 2004-01-30 | 2005-08-11 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
WO2005073216A2 (en) | 2004-01-30 | 2005-08-11 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
WO2007014926A1 (en) | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
WO2008092955A1 (en) | 2007-02-01 | 2008-08-07 | Tibotec Pharmaceuticals Ltd. | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
WO2010072742A1 (en) | 2008-12-23 | 2010-07-01 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
WO2011113859A1 (en) * | 2010-03-16 | 2011-09-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
Non-Patent Citations (4)
Title |
---|
AHLBRECHT H ET AL: "Stereoselective Synthesis, EPC Synthesis by Optical Resolution", 1 January 1995, METHODS OF ORGANIC CHEMISTRY. STEREOSELECTIVE SYNTHESIS; [METHODEN DER ORGANISCHEN CHEMIE], STUTTGART, THIEME VERLAG, DE, PAGE(S) 81 - 101, ISBN: 978-3-13-219504-2, XP002594193 * |
BARTLETT PAUL A ET AL: "Total synthesis of brefeldin A", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC; US, vol. 100, no. 15, 1 January 1978 (1978-01-01), pages 4858 - 4865, XP002448100, ISSN: 0002-7863, DOI: 10.1021/JA00483A036 * |
HONDA ET AL., TETRAHEDRON LETTERS, vol. 22, no. 28, 1981, pages 2679 - 2682 |
ROSENQUIST ET AL., ACTA CHEMICA SCANDINAVICA, vol. 46, 1992, pages 1127 - 1129 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016157058A1 (en) | 2015-03-27 | 2016-10-06 | Janssen Pharmaceuticals, Inc. | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
Also Published As
Publication number | Publication date |
---|---|
TW201329074A (en) | 2013-07-16 |
MX2014003509A (en) | 2014-07-22 |
JP2014528943A (en) | 2014-10-30 |
CN103906739A (en) | 2014-07-02 |
US9227965B2 (en) | 2016-01-05 |
IL231024A0 (en) | 2014-03-31 |
MX356686B (en) | 2018-06-07 |
JP6235473B2 (en) | 2017-11-22 |
KR20140063726A (en) | 2014-05-27 |
CN107011339A (en) | 2017-08-04 |
IL231024A (en) | 2017-09-28 |
EP2758386A1 (en) | 2014-07-30 |
TWI565704B (en) | 2017-01-11 |
EA201490675A1 (en) | 2014-08-29 |
US20140228574A1 (en) | 2014-08-14 |
AU2012311461A1 (en) | 2014-03-06 |
CA2845720A1 (en) | 2013-03-28 |
BR112014006984A2 (en) | 2017-04-04 |
CL2014000687A1 (en) | 2014-08-01 |
HK1199449A1 (en) | 2015-07-03 |
CN103906739B (en) | 2016-12-28 |
AR087993A1 (en) | 2014-04-30 |
AU2012311461B2 (en) | 2017-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2121674B1 (en) | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv | |
EP2382198B1 (en) | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv | |
EP2547645B1 (en) | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv | |
AU2012311461B2 (en) | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | |
RU2588132C2 (en) | Methods and intermediate compounds for producing macrocyclic hepatitis c virus protease inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12762583 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2845720 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 231024 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2012311461 Country of ref document: AU Date of ref document: 20120921 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014531241 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014000687 Country of ref document: CL Ref document number: 14345980 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20147007588 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/003509 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201490675 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014006984 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014006984 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140324 |